Primary Myelofibrosis Market Growth Accelerates: Strategic Forecast Predicts $1.07 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Primary Myelofibrosis Industry Market Size Be by 2025?
In recent years, the market size for primary myelofibrosis has experienced robust growth. From 2024 to 2025, it is projected to increase from $0.79 billion to $0.84 billion, equating to a compound annual growth rate (CAGR) of 6.4%. This growth during the historical period can be linked to several factors such as enhanced disease understanding by clinicians, growing utilization of jak inhibitors, advancement in diagnostic and genetic testing capacities, improved patient accessibility to hematology specialists, and a surge in clinical trial activities.

What's the Long-Term Growth Forecast for the Primary Myelofibrosis Market Size Through 2029?
The market size for primary myelofibrosis is projected to experience robust growth in the coming years. It is set to increase to $1.07 billion by 2029 with a compound annual growth rate (CAGR) of 6.2%. The growth during the forecasted period is due to increasing pipeline of innovative therapies, escalating demand for treatments that modify the disease, the rise in its prevalence among the aged population, mounting focus on combined therapies, and increased funding from pharmaceutical and biotech companies. Key trends for the forecasted period involve enhancements in targeted drug development, incorporation of next-generation sequencing (ngs) in diagnostic procedures, monitoring solutions powered by technology, progress in the protocols of combination therapy, and improvements in imaging techniques for bone marrow fibrosis.

View the full report here:
https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

What Are the Key Growth Drivers Fueling the Primary Myelofibrosis Market Expansion?
The escalating incidence of myelofibrosis is anticipated to spur the progression of the primary myelofibrosis market. A rare form of bone marrow cancer, myelofibrosis interferes with the normal blood cell production in the body, causing significant scarring in the bone marrow that leads to severe anemia, weakness, fatigue, and a swollen spleen. The rise in cases is mainly due to an aging population, as individuals over 60 are most likely to be affected. The increase in life expectancy further fuels the number of diagnosed cases. This enhanced incidence of myelofibrosis facilitates the management of the condition by stimulating research, promoting early diagnosis, diversifying treatment options, and boosting improved clinical guidelines and specialized care. Take, for example, a report released in November 2024 by the National Institute for Health and Care Excellence, an independent executive non-departmental public body based in the UK, stated that the prevalence of myelofibrosis is 3.2 per 100,000 people in the UK with an incidence rate of 0.6 per 100,000. Hence, the rising incidence of myelofibrosis is driving the expansion of the primary myelofibrosis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

What Are the Key Trends Driving Primary Myelofibrosis Market Growth?
The primary myelofibrosis market is seeing a shift in focus amongst leading companies, as they aim to innovate their product lineup with the introduction of items such as Janus kinase 2 inhibiting tablets. These oral medications are designed to obstruct the functioning of the JAK2 enzyme, thus disrupting abnormal signaling pathways that are known to trigger excessive production of blood cells in primary myelofibrosis patients. In doing so, these tablets can reduce the size of the spleen, relieve symptoms of fatigue and bone pain, and impede the advancement of the disease. For example, GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotechnology firm based in Korea, premiered Omjjara (momelotinib) as a novel myelofibrosis treatment in March 2025. This drug has been sanctioned by South Korea's Ministry of Food and Drug Safety and is designed for adult patients living with intermediate- or high-risk primary or secondary myelofibrosis as well as moderate to severe anemia. Omjjara is an oral medication that restrains Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), thereby effectively mitigating symptoms such as anemia, spleen enlargement, and fatigue. Support for its approval is based on clinical trial data that shows substantial improvements in anemia, spleen size, and overall symptoms compared to previously available treatments.

How Is the Primary Myelofibrosis Market Segmented?
The primary myelofibrosis market covered in this report is segmented -

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types
2) By Services: Treatment, Diagnosis
3) By Dosage Forms: Solid, Liquids, Other Dosage Forms
4) By Age: Adult, Child, Geriatric
5) By End User: Hospitals, Clinics, Other End Users

Subsegments:
1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations
2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis
3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders
4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24669&type=smp

Which Companies Are Leading the Charge in Primary Myelofibrosis Market Innovation?
Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Which Regions Are Leading the Global Primary Myelofibrosis Market in Revenue?
North America was the largest region in the primary myelofibrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24669

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.